Determination of Immediate


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 26 05 2020
revised: 15 06 2020
accepted: 16 06 2020
entrez: 5 7 2020
pubmed: 6 7 2020
medline: 14 7 2020
Statut: ppublish

Résumé

The antiproliferative effects of cold atmospheric plasma (CAP) make it a promising application option in oncology. The aim of the present study was to examine whether short-term CAP treatment leads to an initial partial elimination of the treated cells or to long-term impairement and inhibition of cell growth. Cells were treated with CAP and biostatistical modelling was used to estimate growth rates over the incubation time. Four cell lines (U2-OS and MNNG osteosarcoma cells, 3T3 fibroblasts, HaCaT keratinocytes) and three CAP sources (MiniJet-R, kINPen MED, Maxium) were used. The antiproliferative efficacy of CAP was due to a significant reduction in cell count during treatment and the long-lasting inhibition of growth rate in the remaining cells, detectable in all cell lines and after treatment using all three CAP devices. Induction of cell death and inhibition of cell growth are part of a general mechanism of biological CAP efficacy. However, data contradict the hypothesis that cancer cells respond more sensitively to CAP treatment compared to non-malignant cells.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
The antiproliferative effects of cold atmospheric plasma (CAP) make it a promising application option in oncology. The aim of the present study was to examine whether short-term CAP treatment leads to an initial partial elimination of the treated cells or to long-term impairement and inhibition of cell growth.
MATERIALS AND METHODS METHODS
Cells were treated with CAP and biostatistical modelling was used to estimate growth rates over the incubation time. Four cell lines (U2-OS and MNNG osteosarcoma cells, 3T3 fibroblasts, HaCaT keratinocytes) and three CAP sources (MiniJet-R, kINPen MED, Maxium) were used.
RESULTS RESULTS
The antiproliferative efficacy of CAP was due to a significant reduction in cell count during treatment and the long-lasting inhibition of growth rate in the remaining cells, detectable in all cell lines and after treatment using all three CAP devices.
CONCLUSION CONCLUSIONS
Induction of cell death and inhibition of cell growth are part of a general mechanism of biological CAP efficacy. However, data contradict the hypothesis that cancer cells respond more sensitively to CAP treatment compared to non-malignant cells.

Identifiants

pubmed: 32620613
pii: 40/7/3743
doi: 10.21873/anticanres.14363
doi:

Substances chimiques

Plasma Gases 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3743-3749

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Lyubomir Haralambiev (L)

Department of Trauma, Reconstructive Surgery and Rehabilitation Medicine, University Medicine Greifswald, Greifswald, Germany.
Department of Trauma and Orthopaedic Surgery, BG Klinikum Unfallkrankenhaus Berlin gGmbH, Berlin, Germany.

Arnab Bandyophadyay (A)

Institute of Bioinformatics, University Medicine Greifswald, Greifswald, Germany.

Bettina Suchy (B)

Department of Trauma, Reconstructive Surgery and Rehabilitation Medicine, University Medicine Greifswald, Greifswald, Germany.

Martin Weiss (M)

Department of Women's Health Tübingen, Tübingen, Germany.

Axel Kramer (A)

Institute of Hygiene and Environmental Medicine, University Medicine Greifswald, Greifswald, Germany.

Sander Bekeschus (S)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP Greifswald), Greifswald, Germany.

Axel Ekkernkamp (A)

Department of Trauma, Reconstructive Surgery and Rehabilitation Medicine, University Medicine Greifswald, Greifswald, Germany.
Department of Trauma and Orthopaedic Surgery, BG Klinikum Unfallkrankenhaus Berlin gGmbH, Berlin, Germany.

Alexander Mustea (A)

Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany.

Lars Kaderali (L)

Institute of Bioinformatics, University Medicine Greifswald, Greifswald, Germany.

Matthias B Stope (MB)

Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany matthias.stope@ukbonn.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH